Organization: Health Canada
Year: 2023
Month: July
Request Number: A-2023-000520
Request Summary: For each quarter between July 1st, 2022 and June 30th, 2023. Information on the following drugs; Hemophilia A: BeneFIX, Rixubis, Alprolix, Rebinyn, and Immunine. Hemophilia B: Kovaltry, Nuwiq, Zonovate, Xyntha, Esperoct, Jivi, Eloctate, Adynovate, Hemlibra, Alphanate, Humate-P, and Wilate. Bypassing Agents: NiaStase, Obizur, Sevenfact, and FEIBA. Hereditary Angioedema: Orladeyo, Takhzyro, Firazyr, Cinryze, Berinert, Haegarda, Tranexamic Acid, and Danazol. The total volume purchased of each drug by the Canadian Blood Services.
Disposition: No records exist
Number of pages: 0